Showing 1301-1310 of 5603 results for "".
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
https://reachmd.com/programs/cme/emerging-clinical-evidence-for-b7-h3directed-adcs-in-es-sclc-from-esmo-2025/39978/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
https://reachmd.com/programs/cme/guideline-recommendations-in-first-line-treatment-of-her2-negative-upper-gi-cancers/37689/Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-MakingENDOVOICE Live: Endometriosis—A Chronic Burden of Reproductive Years
https://reachmd.com/programs/cme/endovoice-live-endometriosisa-chronic-burden-of-reproductive-years/37176/ENDOVOICE Live: Endometriosis—A Chronic Burden of Reproductive YearsTaking Action Against RSV: No Child Unprotected
https://reachmd.com/programs/cme/taking-action-against-rsv-no-child-unprotected/39307/Overview of RSV epidemiology, prevention options, AAP immunization guidance, and approaches to parent–clinician communication.Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC
https://reachmd.com/programs/cme/sequencing-systemic-and-local-therapy-in-her2-overexpressing-metastatic-nsclc/56520/Apply clinical evidence and multidisciplinary strategies to select and sequence systemic and local therapies for brain metastases in breast and lung cancer.Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers
https://reachmd.com/programs/cme/pivotal-data-in-anti-pd-1-strategies-for-her2-negative-upper-gi-cancers/37690/Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-MakingManaging Brain Metastases Through Multidisciplinary Team Collaboration
https://reachmd.com/programs/cme/managing-brain-metastases-through-multidisciplinary-team-collaboration/56522/Apply clinical evidence and multidisciplinary strategies to select and sequence systemic and local therapies for brain metastases in breast and lung cancer.RAS Across Tumors: Who to Test When
https://reachmd.com/programs/cme/ras-across-tumors-who-to-test-when/54117/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Movements With Meaning: Reading the Pattern, Not the Label
https://reachmd.com/programs/cme/movements-with-meaning-reading-the-pattern-not-the-label/54715/Explore how clinicians differentiate tardive dyskinesia from other movement disorders using clinical features, medication timing, and response patterns.Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
https://reachmd.com/programs/cme/quick-case-strategizing-treatment-selection-in-her2-pd-l1-gastric-cancer/37692/Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-Making